Urocidin News and Research

RSS
Urocidin is a formulation of MCC, a sterile mycobacterial cell wall-DNA complex composition that has a dual mode of action: immune stimulation and direct anticancer activity. Urocidin is formulated for the treatment of bladder cancer, where it is administered by trans-urethral catheter directly into the bladder, coming into contact with immune system cells and bladder cancer cells.
Bioniche Life Sciences sells Animal Health business to Vétoquinol

Bioniche Life Sciences sells Animal Health business to Vétoquinol

Vétoquinol acquires Bioniche's Animal Health business

Vétoquinol acquires Bioniche's Animal Health business

Bioniche Life Sciences announces financial results for first quarter of Fiscal 2014

Bioniche Life Sciences announces financial results for first quarter of Fiscal 2014

Bioniche, Paladin close debt refinancing agreement and sign first licensing deal for Urocidin

Bioniche, Paladin close debt refinancing agreement and sign first licensing deal for Urocidin

Endo, Bioniche decide to end second Urocidin Phase III trial on non-muscle-invasive bladder cancer

Endo, Bioniche decide to end second Urocidin Phase III trial on non-muscle-invasive bladder cancer

Bioniche receives U.S. and Canadian approval for first of two canine oncology products

Bioniche receives U.S. and Canadian approval for first of two canine oncology products

Positive interim results from new bladder cancer therapy trial

Positive interim results from new bladder cancer therapy trial

Endo and Bioniche present Urocidin Phase III trial preliminary results at 2011 AUA annual meeting

Endo and Bioniche present Urocidin Phase III trial preliminary results at 2011 AUA annual meeting

Urocidin Phase III non-muscle-invasive bladder cancer trial interim results to be presented at EAU, AUA conferences

Urocidin Phase III non-muscle-invasive bladder cancer trial interim results to be presented at EAU, AUA conferences

Endo Pharmaceuticals, Bioniche announce first patient enrollment in Urocidin second Phase III trial

Endo Pharmaceuticals, Bioniche announce first patient enrollment in Urocidin second Phase III trial

Bioniche Life Sciences announces completion of Australian Offer and raises gross proceeds of A$12.5 million

Bioniche Life Sciences announces completion of Australian Offer and raises gross proceeds of A$12.5 million

Bioniche's achievement of fourth milestone in Urocidin Phase III trial triggers $4.0M payment from Endo

Bioniche's achievement of fourth milestone in Urocidin Phase III trial triggers $4.0M payment from Endo

Bioniche Life Sciences announces first quarter fiscal 2011 results

Bioniche Life Sciences announces first quarter fiscal 2011 results

Bioniche reduces net loss per share from $0.15 in fiscal 2009 to $0.02 in fiscal 2010

Bioniche reduces net loss per share from $0.15 in fiscal 2009 to $0.02 in fiscal 2010

Bioniche provides update on Urocidin clinical development program for non-muscle-invasive bladder cancer

Bioniche provides update on Urocidin clinical development program for non-muscle-invasive bladder cancer

Bioniche third-quarter consolidated revenues increase 111% to $15.6 million

Bioniche third-quarter consolidated revenues increase 111% to $15.6 million

Bioniche Life Sciences meets obligations under licensing agreement with Endo Pharmaceuticals

Bioniche Life Sciences meets obligations under licensing agreement with Endo Pharmaceuticals

Second-quarter fiscal 2010 results announced by Bioniche Life Sciences

Second-quarter fiscal 2010 results announced by Bioniche Life Sciences

Bioniche Life Sciences announces financial results for its Fiscal 2010 first-quarter

Bioniche Life Sciences announces financial results for its Fiscal 2010 first-quarter

Bioniche Life Sciences' revenue increases by 21% for the fiscal year 2009

Bioniche Life Sciences' revenue increases by 21% for the fiscal year 2009